Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: "mild cognitive impairment" Condition: Alzheimer's Disease Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

NCT01044758
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Levetiracetam 62.5mg, Levetiracetam 125mg, Levetiracetam 250mg, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 13, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 IGIV, 10% in Alzheimer´s Disease

NCT01524887
View directory record Official record
Conditions
Alzheimer´s Disease
Interventions
Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
50 Years to 89 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 13, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

NCT05565833
View directory record Official record
Conditions
Insomnia, Cognitive Dysfunction, Mild Cognitive Impairment, Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic, Dyssomnias, Sleep Wake Disorders, Nervous System Diseases, Alzheimer Disease
Interventions
SHUTi OASIS, Patient Education
Behavioral · Other
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease

NCT02984540
View directory record Official record
Conditions
Mild Cognitive Impairment, Insulin Resistance
Interventions
Low-Carbohydrate Diet, Low-Fat Diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 13, 2026, 5:10 AM EDT
Enrolling by invitation No phase listed Observational

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

NCT05999084
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care
Drug · Combination Product
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Albany, Georgia • Atlanta, Georgia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 13, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

NCT00031018
View directory record Official record
Conditions
Memory Disorders, Alzheimer's Disease
Interventions
Aricept, IFN-alpha2A
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2008 · Synced Oct 13, 2026, 5:10 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

NCT06548191
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Alzheimer's Disease
Interventions
Time-restricted eating
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Results available

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

NCT04730635
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
55 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Long Beach, California • Hallandale, Florida • Lady Lake, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

NCT01992380
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Newport Beach, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00428090
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 13, 2026, 5:10 AM EDT
Withdrawn No phase listed Observational

Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.

NCT03816228
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807 Flortaucipir
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 13, 2026, 5:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mindfulness for Cognition in Early-stage Alzheimer's Disease

NCT06792877
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging, Healthy Elderly, Alzheimer&Amp;Amp;#39;s Dementia (AD)
Interventions
Mindfulness Intervention, Waitlist then mindfulness
Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
50 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

Systematic Multi-domain Alzheimer's Risk Reduction Trial

NCT03683394
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
SMARRT Intervention, Health Education Intervention
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
70 Years to 89 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440
View directory record Official record
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

NCT00476008
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Memantine, Placebo
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 13, 2026, 5:10 AM EDT
Withdrawn Phase 2 Interventional

Clinical Trial of AGB101 for Mild Cognitive Impairment

NCT05986721
View directory record Official record
Conditions
Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Interventions
AGB101, Placebo
Drug
Lead sponsor
AgeneBio
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 13, 2026, 5:10 AM EDT
Recruiting Not applicable Interventional

Music Therapy for Patients With Alzheimer's Disease

NCT05151562
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Virtual Music Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 13, 2026, 5:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia
Interventions
CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Drug
Lead sponsor
CuraSen Therapeutics, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • Lafayette, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 13, 2026, 5:10 AM EDT
Active, not recruiting Not applicable Interventional

Multi-Center Study of Sensory Stimulation to Improve Brain Function

NCT03556280
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia Alzheimers, Dementia, Mild, Dementia, Alzheimer Type, Dementia of Alzheimer Type, Dementia, Cognitive Impairment, Mild, Cognitive Decline
Interventions
GammaSense Stimulation System (Active Settings), GammaSense Stimulation System (Sham Settings)
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Delray Beach, Florida • Stuart, Florida • Methuen, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 13, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables

NCT05159557
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions
In-Home Technology System, Limited In-Home Technology
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 13, 2026, 5:10 AM EDT